We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Hims & Hers Health, Inc. (HIMS - Free Report) . Shares have added about 38% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Hims & Hers Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
Hims & Hers Health delivered an earnings per share of 7 cents in fourth-quarter 2025, beating the Zacks Consensus Estimate of 2 cents. However, the metric was down 36.3% from the year-ago period’s figure of 11 cents.
HIMS’ Q4 Revenues in Detail
Hims & Hers registered revenues of $617.8 million in the fourth quarter, up 28.4% year over year. However, the figure lagged the Zacks Consensus Estimate by 0.2%.
Solid revenues from the Online channel drove the top line.
Hims & Hers’ Geographical Results
In the fourth quarter of 2025, revenues in the United States improved 16.8% year over year to $554.1 million.
Rest of the World revenues grossed $63.7 million, up from the year-ago quarter’s $6.9 million.
Hims & Hers’ Segment Details
In the quarter under review, Online Revenues of $609.1 million reflected a surge of 29.4% year over year on a reported basis.
During the reported quarter, subscribers were 2.5 million, up 12.7% year over year. Monthly online revenue per average subscriber increased 10.7% year over year to $83 in the fourth quarter. Per management, incremental insights and data from new offerings, like Labs, will likely enable HIMS to better attract potential consumers for treatments across newer specialties, such as hormonal support. The company believes this will increase subscriber engagement and has already seen early success signals with the increase in monthly revenue per average subscriber.
Wholesale Revenues totaled $8.7 million, down 16.1% year over year.
HIMS’ Q4 Margin Analysis
In the fourth quarter of 2025, Hims & Hers’ gross profit increased 20.3% year over year to $444.4 million. However, the gross margin contracted 487 basis points (bps) to 71.9%.
Marketing expenses increased 7.7% year over year to $238 million, while technology and development expenses jumped 72.5% to $40.9 million. General and administrative expenses rose 58.6% year over year to $76.2 million, while operations and support expenses increased 37.9% to $80.1 million. Operating expenses of $435.2 million increased 24% year over year.
Operating profit totaled $9.2 million, reflecting a 50.6% plunge from the year-ago quarter. The operating margin in the fourth quarter contracted 238 bps to 1.5%.
Hims & Hers’ Financial Position
Hims & Hers exited 2025 with cash and cash equivalents and short-term investments of $577.5 million compared with $300.3 million at the end of 2024.
Cumulative net cash provided by operating activities at the end of 2025 was $300 million compared with $251.1 million a year ago.
HIMS’ Q1 & 2026 Outlook
Hims & Hers has provided its revenue outlook for the first quarter and initiated the same for 2026.
The company projects revenues for the first quarter of 2026 in the range of $600 million to $625 million, reflecting an uptick of 2%-7% year over year. The Zacks Consensus Estimate is pegged at $645.3 million.
For the full year, HIMS projects revenues in the range of $2.7 billion to $2.9 billion (representing growth of 15%-24% from 2025 levels). The Zacks Consensus Estimate is pegged at $2.73 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -88.38% due to these changes.
VGM Scores
At this time, Hims & Hers Health has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Hims & Hers Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Hims & Hers Health belongs to the Zacks Medical Info Systems industry. Another stock from the same industry, Hinge Health Inc. (HNGE - Free Report) , has gained 2% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025.
Hinge Health Inc. reported revenues of $170.73 million in the last reported quarter, representing a year-over-year change of 0%. EPS of $0.49 for the same period compares with $0.00 a year ago.
For the current quarter, Hinge Health Inc. is expected to post earnings of $0.38 per share, indicating a change of 0% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Hinge Health Inc.. Also, the stock has a VGM Score of F.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?
A month has gone by since the last earnings report for Hims & Hers Health, Inc. (HIMS - Free Report) . Shares have added about 38% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Hims & Hers Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.
Hims & Hers Q4 Earnings Beat Estimates, Margins Contract
Hims & Hers Health delivered an earnings per share of 7 cents in fourth-quarter 2025, beating the Zacks Consensus Estimate of 2 cents. However, the metric was down 36.3% from the year-ago period’s figure of 11 cents.
HIMS’ Q4 Revenues in Detail
Hims & Hers registered revenues of $617.8 million in the fourth quarter, up 28.4% year over year. However, the figure lagged the Zacks Consensus Estimate by 0.2%.
Solid revenues from the Online channel drove the top line.
Hims & Hers’ Geographical Results
In the fourth quarter of 2025, revenues in the United States improved 16.8% year over year to $554.1 million.
Rest of the World revenues grossed $63.7 million, up from the year-ago quarter’s $6.9 million.
Hims & Hers’ Segment Details
In the quarter under review, Online Revenues of $609.1 million reflected a surge of 29.4% year over year on a reported basis.
During the reported quarter, subscribers were 2.5 million, up 12.7% year over year. Monthly online revenue per average subscriber increased 10.7% year over year to $83 in the fourth quarter. Per management, incremental insights and data from new offerings, like Labs, will likely enable HIMS to better attract potential consumers for treatments across newer specialties, such as hormonal support. The company believes this will increase subscriber engagement and has already seen early success signals with the increase in monthly revenue per average subscriber.
Wholesale Revenues totaled $8.7 million, down 16.1% year over year.
HIMS’ Q4 Margin Analysis
In the fourth quarter of 2025, Hims & Hers’ gross profit increased 20.3% year over year to $444.4 million. However, the gross margin contracted 487 basis points (bps) to 71.9%.
Marketing expenses increased 7.7% year over year to $238 million, while technology and development expenses jumped 72.5% to $40.9 million. General and administrative expenses rose 58.6% year over year to $76.2 million, while operations and support expenses increased 37.9% to $80.1 million. Operating expenses of $435.2 million increased 24% year over year.
Operating profit totaled $9.2 million, reflecting a 50.6% plunge from the year-ago quarter. The operating margin in the fourth quarter contracted 238 bps to 1.5%.
Hims & Hers’ Financial Position
Hims & Hers exited 2025 with cash and cash equivalents and short-term investments of $577.5 million compared with $300.3 million at the end of 2024.
Cumulative net cash provided by operating activities at the end of 2025 was $300 million compared with $251.1 million a year ago.
HIMS’ Q1 & 2026 Outlook
Hims & Hers has provided its revenue outlook for the first quarter and initiated the same for 2026.
The company projects revenues for the first quarter of 2026 in the range of $600 million to $625 million, reflecting an uptick of 2%-7% year over year. The Zacks Consensus Estimate is pegged at $645.3 million.
For the full year, HIMS projects revenues in the range of $2.7 billion to $2.9 billion (representing growth of 15%-24% from 2025 levels). The Zacks Consensus Estimate is pegged at $2.73 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -88.38% due to these changes.
VGM Scores
At this time, Hims & Hers Health has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Hims & Hers Health has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Hims & Hers Health belongs to the Zacks Medical Info Systems industry. Another stock from the same industry, Hinge Health Inc. (HNGE - Free Report) , has gained 2% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025.
Hinge Health Inc. reported revenues of $170.73 million in the last reported quarter, representing a year-over-year change of 0%. EPS of $0.49 for the same period compares with $0.00 a year ago.
For the current quarter, Hinge Health Inc. is expected to post earnings of $0.38 per share, indicating a change of 0% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Hinge Health Inc.. Also, the stock has a VGM Score of F.